Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
Celularity Inc. - Class A (CELU)
Company Research
Source: GlobeNewswire
Transaction expected to generate up to $35 million in upfront and milestone paymentsCelularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunityOrganizational realignment reduces operating expenses and sharpens focus on longevity therapeutics FLORHAM PARK, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company focused on longevity science, today announced that it has entered into definitive agreements establishing a strategic commercialization partnership for its placental-derived biomaterials portfolio. The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions. The transaction is intended to monetize Celularity’s commercial biomaterials portfolio while allowing the Company to concentrate resources on advancing its longevity-focused therapeutic pipeline. Under the terms of the agr
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product OpportunitiesGlobeNewswire
- Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy [Yahoo! Finance]Yahoo! Finance
- Celularity Receives $12.2 Million from Sale of New Jersey Net Operating LossesGlobeNewswire
- Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations [Yahoo! Finance]Yahoo! Finance
- Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage DeterminationsGlobeNewswire
CELU
Sec Filings
- 3/10/26 - Form 8-K
- 3/5/26 - Form 8-K
- 2/11/26 - Form SCHEDULE
- CELU's page on the SEC website